GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Market Cap

Pasithea Therapeutics (Pasithea Therapeutics) Market Cap : $6.83 Mil (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pasithea Therapeutics's share price for the quarter that ended in Mar. 2024 was $7.2503. Pasithea Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1.04 Mil. Therefore, Pasithea Therapeutics's market cap for the quarter that ended in Mar. 2024 was $7.56 Mil.

Pasithea Therapeutics's quarterly market cap declined from Sep. 2023 ($10.00 Mil) to Dec. 2023 ($7.71 Mil) and declined from Dec. 2023 ($7.71 Mil) to Mar. 2024 ($7.56 Mil).

Pasithea Therapeutics's annual market cap declined from Dec. 2021 ($40.72 Mil) to Dec. 2022 ($16.71 Mil) and declined from Dec. 2022 ($16.71 Mil) to Dec. 2023 ($7.71 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pasithea Therapeutics's Enterprise Value for Today is $-5.14 Mil.


Pasithea Therapeutics Market Cap Historical Data

The historical data trend for Pasithea Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Market Cap Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- 40.72 16.71 7.71

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.80 12.81 10.00 7.71 7.56

Competitive Comparison of Pasithea Therapeutics's Market Cap

For the Biotechnology subindustry, Pasithea Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Market Cap falls into.



Pasithea Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Pasithea Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.4*1.04158
=$7.71

Pasithea Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$7.2503*1.04325
=$7.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pasithea Therapeutics  (NAS:KTTA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Pasithea Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.
Executives
Graeme Martin Currie officer: Chief Development Officer 51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a 10 percent owner C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd. other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian other: Member of 10% owner group 350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp other: Member of 10% owner group CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc other: Member of 10% owner group 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977

Pasithea Therapeutics (Pasithea Therapeutics) Headlines

From GuruFocus